首页 Emergent BioSolutions(usEBS)-基本信息

Emergent BioSolutions(usEBS)-基本信息

日报更新时间:

周报更新时间:04-11 03:39

行情信息

今开价:74.89

最高价:77.8

成交量:493619.0

昨收价:74.47

最低价:74.42

最新价:77.64

行情图标
概要信息

英文名称:Emergent BioSolutions


行业:医疗


简介:Emergent Biosolutions Inc.是一家专业制药公司,向医疗保健提供商和政府提供专门的产品寻求保护和提高生活品质,用于解决医疗需要和新出现的健康威胁


电话:1-240-6313200


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Emergent BioSolutions是一家跨国专业生物制药公司,总部设在马里兰州盖瑟斯堡,从事开发用于感染性疾病,肿瘤学和自身免疫性疾病的疫苗和抗体治疗剂,并提供用于生物防御目的的医疗装置。Emergent BioSolutions公司著名的产品是BioThrax(Anthrax Vaccine Adsorbed),这是唯一由美国食品和药物管理局(FDA)许可的炭疽疫苗。Emergent BioSolutions公司还为急性血液疾病成人和儿童患者、经历肝移植的某些人、对化疗或放射治疗患者的姑息治疗患者、血友病B患者、高风险水痘(水痘)患者制造疫苗和药品。Emergent BioSolutions分为2个部门来运作:Biodefense 和 Aptevo。 Biodefense部门:销售:BioThrax——治疗炭疽病;Anthrasil——用于吸入炭疽的治疗;BAT——治疗肉毒杆菌病;VIGIV——用于解决天花疫苗接种的不良事件;RSDL——用于从皮肤去除或中和化学试剂,T-2毒素和各种农药相关化学品。开发:NuThrax——下一代炭疽疫苗;UV-4B——预防登革热和流感感染;GC-072——对抗假单胞菌的EV-035系列广谱抗生素的化合物;VAX161C——重组大流行性流感疫苗;PreviThrax——重组保护性抗原炭疽疫苗;以及解决公共健康威胁和新出现的传染病的其他产品。 Aptevo部门:销售:IXINITY——预防血友病B患者的出血事件;WinRho SDF——治疗新生儿的自身免疫性血小板病症和溶血性疾病;HepaGam B——用于乙型肝炎的暴露后预防性治疗;VARIZIG ——暴露后预防性治疗水痘带状疱疹病毒;研究阶段候选产品:otlertuzumab——一种用于慢性淋巴细胞性白血病的蛋白质治疗剂;MOR209/ES414——与MorphoSys AG合作开发,用于转移性去势抵抗性前列腺癌;ES210——炎症相关适应症的蛋白质治疗剂;5E3——阿尔茨海默病的单克隆抗体治疗剂;其他主要用于治疗免疫肿瘤学的蛋白质治疗候选产品。Emergent BioSolutions(EBS)历史百科: 1998年9月5日,BioPort Inc.创立,是Emergent BioSolutions前身; 2003年,Emergent BioSolutions收购Antex Biologics, Inc. 2004年,BioPort更名为Emergent BioSolutions; 2005年,Emergent BioSolutions收购Microscience Ltd.; 2006年,收购Vivacs GmbH; 2006年,Emergent BioSolutions IPO登陆纽交所,股票代码:EBS; 2008年,从Avanir Pharmaceuticals收购一组炭疽单克隆抗体; 2008年,Emergent BioSolutions从VaxGen收购炭疽疫苗项目(Anthrax vaccine program),包括专利; 2010年,Emergent BioSolutions收购Trubion Pharmaceuticals; 2013年,收购Bracco Diagnostics Inc.的医疗保健产品部(Healthcare Protective Products Division),包括RSDL; 2014年,Emergent BioSolutions收购Cangene Corporation; 2016年6月27日,联邦政府的生物医学高级研究与开发管理局(BARDA)与Emergent Biosolutions签订合同,为寨卡病毒(Zika Virus)开发疫苗。

交易日期 交易人 职位 类型 交易份额 价格
2019-05-27 Zoon (Kathryn C.) Director Sell 1376 43.39
2019-05-22 Zoon (Kathryn C.) Director Buy 5736 --
2019-05-22 Sullivan (Louis W) Director Buy 5736 --
2019-05-22 Richard (Ronald B) Director Buy 5736 --
2019-05-22 Joulwan (George A) Director Buy 5736 --
2019-05-22 Hauer (Jerome M) Director Buy 5736 --
2019-05-22 Harsanyi (Zsolt) Director Buy 5736 --
2019-05-22 Bailey (Susan) Director Buy 5736 --
2019-05-07 Strei (Katherine) Officer Sell 237 47.49
2019-05-07 Kramer (Robert G Sr) Chief Executive Officer Sell 95 47.49
2019-05-07 Lindahl (Richard S) Chief Financial Officer Sell 759 47.49
2019-05-06 Sullivan (Louis W) Director Buy 7893 13.37
2019-05-06 Sullivan (Louis W) Director Sell 2135 49.41
2019-03-18 Mulligan (Seamus C) Director Buy 7569 --
2019-03-10 Havey (Adam) Officer Sell 2430 56.93
2019-03-03 Abdun-Nabi (Daniel J) Chief Executive Officer Sell 14565 58.11
2019-02-28 Havey (Adam) Officer Sell 2024 58.20
2019-02-27 Kramer (Robert G Sr) President Sell 1941 58.71
2019-02-27 El-Hibri (Fuad) Chairman of the Board Sell 3826 58.71
2019-02-27 El-Hibri (Fuad) Chairman of the Board Buy 9722 --
2019-02-27 Strei (Katherine) Officer Sell 540 58.71
2019-02-27 Havey (Adam) Officer Sell 812 58.71
2019-02-27 Havey (Adam) Officer Sell 1019 57.92
2019-02-27 Abdun-Nabi (Daniel J) Chief Executive Officer Sell 5101 58.71
2019-02-27 El-Hibri (Fuad) Chairman of the Board Sell 6987 58.47

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Royal Bank of Canada 600512 1.17% -43761 -6.79% 2019-03-31
SSGA Funds Management Inc 1616237 3.13% 18028 1.13% 2019-07-31
Neuberger Berman Investment Advisers LLC 1922108 3.74% 617486 47.33% 2019-03-31
Neuberger Berman Group LLC 1922108 3.74% 617486 47.33% 2019-03-31
Renaissance Technologies Corp 1978402 3.85% 382391 23.96% 2019-03-31
State Street Corporation 2233381 4.35% 266720 13.56% 2019-03-31
Vanguard Group Inc 4704347 9.15% -127954 -2.65% 2019-03-31
BlackRock Fund Advisors 5136308 9.95% 12680 0.25% 2019-07-31
BlackRock Inc 6736576 13.11% 176339 2.69% 2019-03-31
Dimensional Fund Advisors, Inc. 1592790 3.10% -96950 -5.74% 2019-03-31
Dimensional Fund Advisors LP 1352594 2.62% -43925 -3.15% 2019-07-31
Rice Hall James & Associates, LLC 1220454 2.37% -135495 -9.99% 2019-03-31
Vanguard Investments Australia Ltd 1216283 2.36% 3248 0.27% 2019-07-31
Snyder Capital Management LP 1022019 1.99% 55029 5.69% 2019-03-31
Northern Trust Investments Inc 1020228 1.98% 21552 2.16% 2019-07-31
Northern Trust Corp 902561 1.76% 35991 4.15% 2019-03-31
Northern Trust Investments N A 902561 1.76% 35991 4.15% 2019-03-31
T. Rowe Price Associates, Inc. 815657 1.59% 50403 6.59% 2019-03-31
Acadian Asset Management LLC 718984 1.40% 535701 292.28% 2019-03-31
Glenmede Trust Co NA 614269 1.20% 98264 19.04% 2019-03-31
Amvescap Plc. 897588 1.75% -231845 -20.53% 2018-12-31
Geode Capital Management, LLC 1043632 2.03% 575802 123.08% 2018-12-31
BlackRock Asset Management Canada Ltd 6411929 12.47% 58707 0.92% 2019-05-31
Bank of New York Mellon Corp 797594 1.55% -54246 -6.37% 2018-12-31
Goldman Sachs Group Inc 796373 1.55% -233202 -22.65% 2018-12-31
Invesco Capital Management LLC 789517 1.54% -13901 -1.73% 2019-03-31
Goldman Sachs Asset Management, L.P. 829036 1.63% 19574 2.42% 2018-09-30
Standard Life Aberdeen PLC 1097447 2.15% -337882 -23.54% 2018-09-30
Man Group PLC 834665 1.64% 7217 0.87% 2018-06-30
BlackRock Institutional Trust Company NA 1109081 2.18% 131778 13.48% 2018-06-30
Fisher Asset Management, LLC 351575 0.70% -26288 -6.96% 2018-06-30
State Street Corp 1969803 3.94% 239684 13.85% 2018-06-30
Aberdeen Asset Management Inc. 956767 1.91% -68130 -6.65% 2018-08-31
Goldman Sachs Asset Management LP 809462 1.62% 140813 21.06% 2018-06-30
Invesco PowerShares Capital Mgmt LLC 739965 1.48% 74737 11.23% 2018-06-30
Millennium Management LLC 575009 1.15% -342056 -37.30% 2018-06-30
Charles Schwab Investment Management Inc 437243 0.87% -9348 -2.09% 2018-06-30
Peregrine Capital Management Inc 348968 0.70% -17202 -4.70% 2018-03-31
Mellon Capital Management Corporation 349733 0.70% 142308 68.61% 2018-03-31
Quantitative Management Associates LLC 350957 0.70% 291978 495.05% 2018-03-31
Matarin Capital Management LLC 351830 0.71% 26919 8.29% 2018-03-31
NORGES BANK 516628 1.05% 140122 37.22% 2017-12-31
LSV Asset Management 746518 1.51% 90971 13.88% 2017-12-31
Pioneer Investment Mgmt Inc 353957 0.72% 353957 -- 2017-12-31
UBS Asset Mgmt Americas Inc 430649 1.04% -59111 -12.07% 2017-09-30
Fidelity International Ltd 535678 1.29% -63565 -10.61% 2017-09-30
Calamos Advisors LLC 520364 1.26% 476115 1075.99% 2017-12-31
Guggenheim Capital LLC 364277 0.88% -122 -0.03% 2017-09-30
Manufacturers Life Insurance Co 631304 1.54% 15314 2.49% 2017-06-30
Aberdeen Asset Management PLC 1737470 4.23% 118894 7.35% 2017-06-30
Arrowstreet Capital Limited Partnership 738884 1.82% 205144 38.44% 2016-09-30
D. E. Shaw & Co LP 533649 1.32% -308924 -36.66% 2016-09-30
Bank of New York Mellon 2964008 3.00% 85244870 0.10% 1999-11-30
BlackRock, Inc. 2774801 3.00% 79803277 0.10% 1999-11-30
Loomis, Sayles & Co., L.P. 2078413 3.00% 59775158 -- 1999-11-30
Broadfin Capital LLC 2066719 3.00% 59438838 -- 1999-11-30
The Vanguard Group, Inc. 2057086 3.00% 59161793 -- 1999-11-30
Intervac, L.L.C. 1993919 3.00% 57345110 -- 1999-11-30
Fuad El-Hibri 5789439 3.00% 166504266 0.20% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Goldman Sachs Small Cap Value Fund 271430 0.53% 120446 79.77% 2019-06-30
Vanguard Extended Market Index Fund 621940 1.21% -2833 -0.45% 2019-06-30
Vanguard Small Cap Growth Index Fund 638297 1.24% -3088 -0.48% 2019-06-30
iShares Russell 2000 ETF 1010532 1.96% 15814 1.59% 2019-07-30
Vanguard Small Cap Index 1113678 2.16% -15817 -1.40% 2019-06-30
Vanguard Total Stock Market Index Fund 1204839 2.33% 273 0.02% 2019-06-30
SPDR 1210379 2.35% 18825 1.58% 2019-07-31
Neuberger Berman Genesis Fund 1569980 3.04% 207090 15.19% 2019-06-30
iShares Core S&P Small-Cap ETF 2741432 5.31% 2629 0.10% 2019-07-30
T. Rowe Price QM US Small-Cap Gr Eq Fd 571200 1.11% -- -- 2019-06-30
Harbor Small Cap Value Fund 456154 0.88% 406353 815.95% 2019-06-30
DFA US Small Cap Portfolio 448256 0.87% -- -- 2019-05-31
Fidelity 271450 0.53% -30400 -10.07% 2019-06-30
Principal SmallCap S&P 600 Idx SP 284903 0.55% 553 0.19% 2019-06-30
iShares S&P Small-Cap 600 Value ETF 288691 0.56% -- -- 2019-07-30
Franklin Small Cap Growth Fund 348300 0.68% 93700 36.80% 2019-06-30
Vanguard Tax Managed Small Cap Fund 389988 0.76% -- -- 2019-06-30
iShares S&P Small-Cap 600 Growth ETF 401378 0.78% -- -- 2019-07-30
iShares Russell 2000 Growth ETF 418902 0.81% 7497 1.82% 2019-07-30
Aberdeen US Small Cap Equity Fund 421105 0.82% 30716 7.87% 2019-06-30
Invesco S&P SmallCap Health Care ETF 270991 0.53% -- -- 2019-06-30
Glenmede Small Cap Equity Portfolio 543792 1.06% 92292 20.44% 2019-03-31
Glenmede Small Cap Equity Tr 543792 1.06% 92292 20.44% 2019-03-31
iShares Core MSCI AllCntry Wld exCan ETF 2721677 5.30% 7230 0.27% 2019-05-22
iShares Core S&P US Total Market ETF 2704995 5.26% -- -- 2019-05-30
iShares US Small Cap ETF (CAD-Hedged) 934369 1.82% -1566 -0.17% 2019-05-30
Vanguard Small Cap Index Fund 1134615 2.21% 7668 0.68% 2019-04-30
DFA US Targeted Value Portfolio 269157 0.52% -28057 -9.44% 2019-03-31
Vanguard Explorer Fund 273358 0.53% -3680 -1.33% 2018-12-31
Columbia Small Cap Index Fund 245359 0.48% -3730 -1.50% 2019-01-31
Vanguard Global Equity Fund 280291 0.55% -17022 -5.73% 2018-09-30
Invesco Dynamic Pharmaceuticals ETF 245525 0.48% -- -- 2018-11-29
iShares Russell 2000 Growth 431471 0.84% -416 -0.10% 2018-09-12
Northern Small Cap Value 261933 0.52% -- -- 2018-06-30
Vanguard Explorer Inv 273582 0.55% -- -- 2018-06-30
Vanguard Global Equity Inv 297313 0.59% -20971 -6.59% 2018-06-30
PowerShares Dynamic Pharmaceuticals ETF 255190 0.50% -- -- 2018-09-13
Aberdeen US Small Cap Equity A 956767 1.91% -68130 -6.65% 2018-08-31
Vanguard Total Stock Mkt Idx 1061338 2.12% 1426 0.13% 2018-07-31
Glenmede Small Cap Equity Adv 739053 1.48% -83658 -10.17% 2018-06-30
iShares S&P Small-Cap 600 Growth 615888 1.20% 7803 1.28% 2018-09-12
Vanguard Small Cap Growth Index Inv 607642 1.21% 9180 1.53% 2018-07-31
PowerShares S&P SmallCap Health Care ETF 447755 0.87% 9376 2.14% 2018-09-13
Vanguard Extended Market Idx Inv 465725 0.93% 1200 0.26% 2018-07-31
Vanguard Tax-Managed Small Cap Adm 293773 0.59% 10800 3.82% 2018-07-31
DFA US Targeted Value I 335001 0.67% -- -- 2018-07-31
T. Rowe Price QM US Small-Cap Growth Eq 427000 0.85% 200600 88.60% 2018-06-30
Goldman Sachs Small Cap Value A 455388 0.91% 38417 9.21% 2018-06-30
DFA US Small Cap I 448256 0.90% -- -- 2018-07-31
DFA US Micro Cap I 264333 0.53% -37353 -12.38% 2018-05-31
Wells Fargo Small Company Growth Admin 222853 0.45% -2082 -0.93% 2018-04-30
CREF Stock R1 209348 0.42% 54545 35.24% 2018-03-31
Columbia Small Cap Index Z 178069 0.36% -- -- 2018-02-28
Schwab Health Care 230900 0.47% -18800 -7.53% 2017-12-31
Schwab Small-Cap Equity 221176 0.55% -- -- 2016-12-31
TIAA-CREF Small-Cap Equity Instl 310882 0.77% 58400 23.13% 2016-12-31
Goldman Sachs Small/Mid Cap Growth A 294651 0.73% -30507 -9.38% 2016-12-31
iShares S&P Small-Cap 600 Value 270830 0.65% 379 0.14% 2017-02-07
Dreyfus Opportunistic Small Cap 200858 0.53% -48536 -19.46% 2016-04-30
Vanguard Strategic Small-Cap Equity Inv 239300 0.59% 63498 36.12% 2016-09-30
Dreyfus Opportunistic Small Cap Fund 761531 2.00% -42497 -5.30% 2015-09-30
SPDR® S&P Biotech ETF 757573 2.30% 2374 0.30% 2015-11-27
iShares Russell 2000 (AU) 495365 1.50% -303 -0.10% 2015-11-27
Loomis Sayles Small Cap Growth Fund 447878 1.10% 3777 0.80% 2015-09-30
Swedbank Robur Medica 425465 1.10% -- -- 2015-10-31
DFA U.S. Micro Cap Portfolio 400851 1.00% 6626 1.70% 2015-09-30
PowerShares Dynamic Biotech&Genome Port 365571 1.10% -- -- 2015-11-29
Fidelity® Select Biotechnology Portfolio 336186 0.90% -- -- 2015-10-31
DFA U.S. Small Cap Portfolio 318786 0.80% -- -- 2015-09-30
iShares Core S&P Small-Cap (AU) 790401 2.40% -- -- 2015-11-27

Robert G. Kramer Robert G. Kramer holds the position of President, CEO, COO & Director at Emergent BioSolutions, Inc. In the past Mr. Kramer occupied the position of President for Emergent BioDefense Operations Lansing, Inc. He received an MBA from the University of Western Kentucky and an undergraduate degree from Clemson University.
Richard S. Lindahl Currently, Richard S. Lindahl holds the position of Chief Financial Officer, Treasurer & Executive VP of Emergent BioSolutions, Inc. He previously occupied the position of Chief Financial Officer at CEB, Inc., Vice President-Finance for Youghiogheny Communications-Texas LLC, Treasurer for Nextel Communications, Inc. and Treasurer & Senior Vice President at Sprint Communications, Inc. Mr. Lindahl received an undergraduate degree from Dartmouth College and an MBA from the University of Virginia Darden School of Business.
Sharon M. Solomon Currently, Sharon M. Solomon holds the position of Chief Information Officer & Senior Vice President of Emergent BioSolutions, Inc. She previously occupied the position of Vice President-Information Technology of AstraZeneca LP, Vice President-Information Technology at Actavis, Inc., Vice President-Information Technology for Actavis, Inc., Chief Information Officer for Jacuzzi Brands Corp. and Chief Information Officer at MedImmune LLC. She received an undergraduate degree and a graduate degree from the University of Maryland.
Darren W. Buchwald Presently, Darren W. Buchwald is Senior Vice President-Sales & Marketing of Emergent BioSolutions, Inc. He previously occupied the position of Product Manager-Celexa Launch Team at PAREXEL International Corp., VP-Commercial Development, Sales & Marketing at Middlebrook Pharmaceuticals, Inc., Associate Director-Strategic Marketing at Human Genome Sciences, Inc. and Product Manager at CareFirst, Inc. Mr. Buchwald received an undergraduate degree from the University of Maryland.
George A. Joulwan George A. Joulwan founded One Team, Inc. Mr. Joulwan is President at this company. He is also on the board of Alion Science & Technology Corp., Emergent BioSolutions, Inc., Washington Consulting, Inc. and Accenture Federal Services LLC. Mr. Joulwan previously held the position of Principal at The United States Army (District of Columbia), Professor at National Defense University and Trustee & Professor at US Military Academy. George A. Joulwan received a graduate degree from Loyola University of Chicago and an undergraduate degree from US Military Academy.
Jerome M. Hauer Jerome M. Hauer is on the board of Emergent BioSolutions, Inc. In his past career Dr. Hauer held the position of Chief Executive Officer at The Hauer Group, Inc., Director-Emergency Medical Services at State of Indiana, Principal at Chertoff Group LLC, Assistant Secretary-Public Health Emergency at US Department of Health & Human Services (DC), SVP & Co-Chairman-Homeland Security Practice at Fleishman-Hillard Government Relations, Member-Medicine Committee at National Academy of Sciences, MD-Crisis & Consequence Management Group at Kroll Associates, Inc. and Member-Improving Clinical Medical Response at Institute of Medicine. Jerome M. Hauer received an undergraduate degree from New York University, an undergraduate degree from Johns Hopkins Bloomberg School of Public Health and a doctorate and a graduate degree from Defence Academy-College of Management & Technology.
Adam R. Havey Adam R. Havey is on the board of Emergent BioSolutions Canada, Inc. and Executive VP- Business Operations at Emergent BioSolutions, Inc. In his past career Mr. Havey was President of Emergent BioDefense Operations Lansing, Inc. Mr. Havey received an undergraduate degree from Michigan State University.
Louis Wade Sullivan Louis Wade Sullivan is a businessperson who founded Medical Education for South African Blacks and who has been at the head of 7 different companies. Presently, he is Chairman at Public Broadcasting Atlanta and Chairman & Chief Executive Officer of The Sullivan Alliance. He is also on the board of United Therapeutics Corp., Emergent BioSolutions, Inc. and America's Public Television Stations and President-Emeritus at Morehouse School of Medicine. Dr. Sullivan previously was Non-Executive Chairman at ANI Pharmaceuticals, Inc., Co-Director-Hematology Division at Boston University Medical Center Hospital, Secretary at US Department of Health & Human Services (DC), Chairman of Medical Education for South African Blacks, Chairman for The National Health Museum, President of Morehouse School of Medicine, Member-National Executive Council at Boy Scouts of America, Assistant Professor at Seton Hall University and Professor at Boston University School of Medicine. Dr. Sullivan received an undergraduate degree from Morehouse College and a doctorate from Boston University School of Medicine.
George A. Joulwan George A. Joulwan founded One Team, Inc. Mr. Joulwan is President at this company. He is also on the board of Alion Science & Technology Corp., Emergent BioSolutions, Inc., Washington Consulting, Inc. and Accenture Federal Services LLC. Mr. Joulwan previously held the position of Principal at The United States Army (District of Columbia), Professor at National Defense University and Trustee & Professor at US Military Academy. George A. Joulwan received a graduate degree from Loyola University of Chicago and an undergraduate degree from US Military Academy.
Ronald B. Richard Mr. Ronald B. Richard is a Lead Independent Director at Emergent BioSolutions, Inc. and a President & Chief Executive Officer at The Cleveland Foundation. He is on the Board of Directors at Emergent BioSolutions, Inc., Council on Foundations, Folio Photonics Inc., Leone Asset Management, Inc. and Ohio Grantmakers Forum. Mr. Richard was previously employed as a President by Stem Cell Preservation Technologies, Inc., a Chief Operating Officer & Managing Director by In-Q-Tel, and a Chairman by The International Biomedical Research Alliance. He also served on the board at Living Cities, Inc. He received his undergraduate degree from the University of Washington and a graduate degree from The Johns Hopkins University.
Christopher W. Frech Presently, Christopher W. Frech holds the position of Senior VP-Global Government Affairs at Emergent BioSolutions, Inc. He received an undergraduate degree from Wheeling Jesuit University and a graduate degree from West Virginia University.
Fuad El Hibri Fuad El Hibri is a businessperson who founded Emergent BioSolutions, Inc. and who has been at the head of 6 different companies. Currently, he holds the position of Chairman of East West Resources Corp., Chairman of Aptevo Therapeutics, Inc. and Executive Chairman for Emergent BioSolutions, Inc. He is also on the board of The International Biomedical Research Alliance and The National Health Museum and Chairman & Treasurer at El-Hibri Charitable Foundation. In his past career he occupied the position of President of Digicel El Salvador Ltd and Chairman & Chief Executive Officer of Emergent BioDefense Operations Lansing, Inc. He received an undergraduate degree from Stanford University and a graduate degree from Yale University.
Daniel J. Abdun-Nabi Presently, Daniel J. Abdun-Nabi occupies the position of Chief Executive Officer & Director at Emergent BioSolutions, Inc. He is also on the board of 5 other companies. He previously was Secretary, SVP-Legal Affairs & General Counsel at North American Vaccine, Inc., General Counsel of BioVeris Corp. and General Counsel at IGEN International, Inc. He received an undergraduate degree from the University of Massachusetts, a graduate degree from the University of San Diego School of Law and a graduate degree from Georgetown University Law Center.
Zsolt P�0�1�0�3l Hars�0�1�0�3nyi Dr. Zsolt P�0�1�0�3l Hars�0�1�0�3nyi is an Independent Director at Aptevo Therapeutics, Inc., a Chairman at Exponential Biotherapies, Inc. and an Independent Director at Emergent BioSolutions, Inc. He is on the Board of Directors at Aptevo Therapeutics, Inc., N-Gene Research Laboratories, Inc., Emergent BioSolutions, Inc. and OptiFilter Research Zrt. Dr. Hars�0�1�0�3nyi was previously employed as a Chairman & Chief Executive Officer by Exponential Biotherapies, Inc., a Founder by DynPort Vaccine Co. LLC, a President by Porton International Plc, and a Vice President-Corporate Finance by E.F. Hutton & Co., Inc. He received his undergraduate degree from Amherst College and a doctorate degree from Albert Einstein College of Medicine, Inc..
Sue Bailey Sue Bailey is on the board of Emergent BioSolutions, Inc., Suburban Hospital Healthcare System (Maryland) and Brady Center to Prevent Gun Violence. Dr. Bailey previously held the position of Administrator at National Highway Traffic Safety Administration. Sue Bailey received an undergraduate degree from the University of Maryland and a doctorate from Philadelphia College of Osteopathic Medicine.
Robert G. Burrows Robert G. Burrows is Vice President-Investor Relations at Emergent BioSolutions, Inc. Mr. Burrows previously was Lead Investor Relations Officer at Sunrise Senior Living, Inc., Vice President-Investor Relations at Gene Logic, Inc. and Lead Investor Relations Officer at Allied Capital Corp. Mr. Burrows received an MBA from Boston University and an undergraduate degree from the University of California, Davis.
Seamus C. Mulligan Seamus C. Mulligan founded Azur Pharma Ltd. Mr. Mulligan is on the board of Emergent BioSolutions, Inc. and Jazz Pharmaceuticals Plc. In his past career he occupied the position of Executive Chairman for Circ Pharma Ltd., Chairman & Chief Executive Officer at Azur Pharma Ltd., Chairman & Chief Executive Officer for Adapt Pharma Ltd. and Vice President-Business & Corporate Development at Elan Corp. Plc. He received a graduate degree and an undergraduate degree from Trinity College Dublin.
Katherine Strei Currently, Katherine Strei holds the position of Chief Human Resources Officer & Executive VP of Emergent BioSolutions, Inc. In her past career she held the position of Director-Executive Development at Federal National Mortgage Association, Manager, Director-Program & Training at Manorcare Health Services, Inc. and Vice President-People & Organization Development at MedImmune LLC. Ms. Strei received an undergraduate degree from Lawrence University and a graduate degree from American University.
W. James Jackson Currently, W. James Jackson is Chief Scientific Officer & Senior Vice President at Emergent BioSolutions, Inc. In his past career Dr. Jackson was President at Antex Biologics Research & Development Corp. and Director-Molecular Biology at MicroCarb, Inc. Dr. Jackson received a doctorate from the University of Georgia and an undergraduate degree from the University of Tennessee.
W. James Jackson Currently, W. James Jackson is Chief Scientific Officer & Senior Vice President at Emergent BioSolutions, Inc. In his past career Dr. Jackson was President at Antex Biologics Research & Development Corp. and Director-Molecular Biology at MicroCarb, Inc. Dr. Jackson received a doctorate from the University of Georgia and an undergraduate degree from the University of Tennessee.
C. Douglas White C. Douglas White is on the board of World Trade Center Institute and Senior Vice President & Head-Devices Business Unit at Emergent BioSolutions, Inc. Mr. White previously occupied the position of Chief Executive Officer & Director at OpGen, Inc., Executive VP & General Manager-Diagnostics at BG Medicine, Inc., Vice President-Global Product Management at Nucleic Acid Diagnostics, Inc., GM-Molecular Diagnostics & Women's Health at Becton Dickinson Diagnostics, Inc., Senior Vice President-Commercial Operations at Digene Corp., Vice President-Marketing at Abbott Diagnostics, Inc., Vice President-Marketing at Chiron Diagnostics Corp., Vice President-US Sales & Marketing at Bayer Diagnostics Corp. and Senior Vice President-Sales & Marketing for Qiagen, Inc. He received an undergraduate degree from Washington College.
Atul Saran Atul Saran holds the position of Secretary & Executive VP-Corporate Development at Emergent BioSolutions, Inc. He is also on the board of Emergent Product Development (UK) Ltd. and LogicNets, Inc. and Member of The District of Columbia Bar. In his past career Mr. Saran was Vice President-Corporate Development & Ventures at AstraZeneca Plc SVP-Corporate Development & Ventures at MedImmune Ventures, Inc. and Vice President-Corporate Development & Ventures at MedImmune LLC (both are subsidiaries of AstraZeneca Plc), Senior Vice President & General Counsel of MacroGenics, Inc., Member of California State Bar Association and Associate Attorney at Hogan & Hartson LLP. Atul Saran received an undergraduate degree from Stanford University, an MBA from MIT Sloan School of Management and a graduate degree from the University of Illinois College of Law.
Laura Saward Laura Saward is SVP & Antibody Therapeutics Business Unit at Emergent BioSolutions, Inc. In the past she occupied the position of Chief Scientific Officer at Cangene Corp. and Member of Manitoba Health Research Council. Dr. Saward received an undergraduate degree from the University of Guelph and a doctorate from the University of Manitoba.
Laura K. Kennedy Currently, Laura K. Kennedy is Senior VP, Chief Ethics & Compliance Officer at Emergent BioSolutions, Inc. She is also Member of The District of Columbia Bar, Member of Massachusetts Bar Association, Member of The Virginia Bar Association and Member-Working Group at Defense Industry Initiative. In her past career she occupied the position of Partner at Jenner & Block LLP, Partner at Seyfarth Shaw LLP, Chief Ethics Officer & Senior VP-Compliance at Science Applications International Corp., Partner at Holland & Knight LLP, Chief Ethics & Compliance Officer at Leidos Holdings, Inc. and VP, Chief Ethics & Global Compliance Officer at Honeywell, Inc. Ms. Kennedy received an undergraduate degree from Oberlin College and a graduate degree from Cornell Law School.
Jeffrey G. Lamothe Dr. Jerome M. Hauer is an Independent Director at Emergent BioSolutions, Inc. He is on the Board of Directors at Emergent BioSolutions, Inc. Dr. Hauer was previously employed as a Chief Executive Officer by The Hauer Group, Inc., a SVP & Co-Chairman-Homeland Security Practice by Fleishman-Hillard Government Relations, an Acting Assistant Secretary-Public Health Emergency by US Department of Health & Human Services (DC), a MD-Crisis & Consequence Management Group by Kroll Associates, Inc., a Principal by Chertoff Group LLC, a Member-Improving Clinical Medical Response by Institute of Medicine, a Member-Medicine Committee by National Academy of Sciences, and a Director-Emergency Medical Services by State of Indiana. He also served on the board at Harbor BioSciences, Inc., Response to Disaster & Emergencies Institute, City of New York (New York), Emergency Management Equipment and Envision Healthcare Corp. /Old/. He received his undergraduate degree from New York University, an undergraduate degree from Johns Hopkins Bloomberg School of Public Health, a graduate degree from Defence Academy-College of Management & Technology and a doctorate degree from Defence Academy-College of Management & Technology.
Jerome M. Hauer Jerome M. Hauer is on the board of Emergent BioSolutions, Inc. In his past career Dr. Hauer held the position of Chief Executive Officer at The Hauer Group, Inc., Director-Emergency Medical Services at State of Indiana, Principal at Chertoff Group LLC, Assistant Secretary-Public Health Emergency at US Department of Health & Human Services (DC), SVP & Co-Chairman-Homeland Security Practice at Fleishman-Hillard Government Relations, Member-Medicine Committee at National Academy of Sciences, MD-Crisis & Consequence Management Group at Kroll Associates, Inc. and Member-Improving Clinical Medical Response at Institute of Medicine. Jerome M. Hauer received an undergraduate degree from New York University, an undergraduate degree from Johns Hopkins Bloomberg School of Public Health and a doctorate and a graduate degree from Defence Academy-College of Management & Technology.
Kathryn C. Zoon Kathryn C. Zoon is on the board of Emergent BioSolutions, Inc. and The International Biomedical Research Alliance and Member of National Academy of Medicine of United States and Member-Earth & Life Studies Division at The National Research Council. In her past career she occupied the position of Deputy Director at Center for Cancer Research, Director-Intramural Research Division at National Institute of Allergy & Infectious Diseases, Director at Center for Biologics Evaluation & Research and President at International Cytokine & Interferon Research. She received an undergraduate degree from Rensselaer Polytechnic Institute and a doctorate from The Johns Hopkins University.
Christopher W. Frech Presently, Christopher W. Frech holds the position of Senior VP-Global Government Affairs at Emergent BioSolutions, Inc. He received an undergraduate degree from Wheeling Jesuit University and a graduate degree from West Virginia University.
John H. Ducote John H. Ducote is Senior Vice President-Global Quality at Emergent BioSolutions, Inc. He received an undergraduate degree from Louisiana State University.
Barbara Solow Barbara Solow is SVP-External Development & Government Contracting at Emergent BioSolutions, Inc.
Sean M. Kirk Sean M. Kirk is SVP-Manufacturing Operations & Head-CDMO Business at Emergent BioSolutions, Inc.

量化对比

全部评论 1

  • 【美国制药公司EBS与强生达成五年协议,支持候选新冠疫苗生产】美国制药公司EBS(EBS.N)(Emergent BioSolutions Inc)周一宣布已与强生公司(JNJ.N)签署一项为期五年的合同,为其生产新冠病毒候选疫苗所需的原料药。根据协议,从明年开始,EBS将在五年内提供大规模原料药生产服务,头两年的价值约为4.8亿美元。EBS也与阿斯利康、Novavax和Vaxart等医药公司签署了类似的协议,以扩大新冠候选疫苗的生产能力。EBS还从美国政府那里获得了6.28亿美元的资金。(界面)

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐